Europe Parenteral Lipid Emulsion Market Report: Market Size & Forecast 2026

Parenteral lipid emulsions are sterile oil-in-water preparations administered intravenously to deliver essential fatty acids and calories to patients unable to receive oral or enteral nutrition. The European market is one of the most established globally, underpinned by advanced healthcare infrastructure, strong regulatory oversight from the European Medicines Agency, and high per-capita spending on clinical nutrition. The market benefits from well-developed hospital pharmacy networks and a growing home parenteral nutrition segment across Western Europe.

• •European market valued at approximately $15.24 billion in 2025
• •Growth driven by clinical nutrition demand across hospital and homecare settings
• •EMA-approved formulations dominate, with strict quality and safety standards

Rising prevalence of chronic illnesses such as cancer, gastrointestinal disorders, and critical care admissions is increasing the need for parenteral nutrition support. Demographic ageing across Europe is expanding the pool of patients requiring long-term nutritional therapy, while technological improvements in emulsion stability and lipid blends are broadening clinical applications. The shift toward home-based parenteral nutrition is also accelerating demand, as healthcare systems seek to reduce inpatient costs.

• •Aging population and rising chronic disease burden across Western and Eastern Europe
• •Growing adoption of home parenteral nutrition to lower hospitalisation costs
• •Innovation in omega-3, olive oil, and MCT-containing emulsion formulations

The market is segmented by generation of lipid emulsion, including first-generation soybean oil-based products, second-generation olive oil and MCT/soy blends, and third-generation fish oil-based formulations with anti-inflammatory properties. By application, use spans hospital inpatient care, ambulatory and home parenteral nutrition, and specialised pharmaceutical compounding. Geographically, Western Europe leads consumption, with Germany, France, the United Kingdom, and Italy representing the largest national markets, while Central and Eastern European countries are showing faster percentage growth as healthcare access expands.

• •Third-generation fish oil emulsions are the fastest-growing product segment
• •Hospitals remain the largest end-user, with homecare expanding rapidly
• •Germany, France, UK, and Italy are the leading country-level markets

What are the recent trends and outlook?

The European parenteral lipid emulsion market is expected to continue its steady expansion through the next decade, supported by clinical guideline updates favouring earlier parenteral nutrition intervention in critically ill patients. Sustainability in pharmaceutical manufacturing, including reduced use of soybean-derived oils, and personalised nutrition approaches are emerging themes shaping product development. Continued investment in home infusion infrastructure and digital patient monitoring is likely to reinforce the shift of lipid emulsion use outside traditional hospital settings.

• •Steady growth expected through the forecast horizon, consistent with the 5.61% CAGR
• •Shift toward third-generation emulsions with improved clinical profiles
• •Expansion of home infusion services and personalised parenteral nutrition protocols